Related Experiment Videos
Reversal of transformed phenotypes by herbimycin A in src oncogene expressed rat fibroblasts
1National Institute of Health, Department of Antibiotics, Tokyo, Japan.
Abstract:
We studied the effectiveness of herbimycin A, an inhibitor of the function of the src oncogene, to reverse the various transformed phenotypes in normal rat kidney (NRK) cells integrating temperature-sensitive v-src (ts/NRK). Elevated glucose transport in ts/NRK cells at a permissive temperature (33 degrees C) was decreased by herbimycin in 8 h to near the level that was observed either in ts/NRK grown at a nonpermissive temperature (39 degrees C) or in untransformed NRK cells at either temperature. Herbimycin caused no significant decrease in glucose uptake in ts/NRK cells grown at 39 degrees C. The effects of herbimycin on serum- and anchorage-independent growth properties of ts/NRK cells and of NRK cells integrating K-ras (KNRK) were also examined. With ts/NRK cells grown at 33 degrees C, the inhibition of cell growth by herbimycin became more pronounced when the serum concentration in the medium was lowered. With KNRK cells, in contrast, almost the same extent of cell growth inhibition was exerted by herbimycin irrespective of the serum concentration. Furthermore, with ts/NRK cells grown at 33 degrees C, herbimycin inhibited the colony formation in the soft agar medium more strongly than on a solid support. No such differential effects were observed with KNRK cells under similar conditions. These results suggest that herbimycin specifically acts on cells expressing the src oncogene and reverses various transformed characteristics to the normal ones.
Insights
Herbimycin A reverses cancer-like cell changes by targeting the src oncogene. This drug effectively normalized glucose transport and growth in src-transformed cells, demonstrating its specific anti-cancer potential.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- The src oncogene drives cellular transformation and associated phenotypes.
- Understanding targeted therapies is crucial for cancer treatment.
Purpose of the Study:
- To investigate herbimycin A's ability to reverse transformed phenotypes in cells expressing the src oncogene.
- To determine if herbimycin A's effects are specific to src oncogene activity.
Main Methods:
- Utilized temperature-sensitive v-src (ts/NRK) and K-ras (KNRK) transformed rat kidney cells.
- Assessed glucose transport, serum-independent growth, and anchorage-independent growth.
- Compared herbimycin A's effects at permissive and non-permissive temperatures and varying serum concentrations.
Main Results:
- Herbimycin A normalized elevated glucose transport in ts/NRK cells at the permissive temperature.
- The drug inhibited cell growth and colony formation in soft agar more effectively in ts/NRK cells compared to KNRK cells.
- Herbimycin A's effects were dependent on src oncogene expression, not K-ras expression.
Conclusions:
- Herbimycin A specifically targets cells expressing the src oncogene.
- The drug effectively reverses multiple transformed cellular characteristics induced by src.
- Herbimycin A shows promise as a targeted therapeutic agent against src-driven cancers.